Showing results (61-70 of 120) with videos related to
Sort By:
Pageof 12
Hematological Oncology|July 24, 2023
Personalised therapy in follicular lymphoma - is the dial turning?Kim M Linton, Lena Specht, Astrid Pavlovsky, et al.Leukemia & Lymphoma|February 18, 2015
Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomasEva Kimby, Björn Östenstad, Peter Brown, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup studyMarinus H J van Oers, Martine Van Glabbeke, Livia Giurgea, et al.Leukemia Research|July 4, 2009
Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemiaMohd Arifin Kaderi, Mahmoud Mansouri, Norafiza Zainuddin, et al.Blood|April 20, 2004
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administrationGeoff Hale, Peppy Rebello, Lee R Brettman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemiaSteven P Treon, Mark Hansen, Andrew R Branagan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2018
Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-UpSandra Lockmer, Bjørn Østenstad, Hans Hagberg, et al.Haematologica|March 6, 2025
Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemiaMagdalena Kättström, Bertil Uggla, Camilla Virta, et al.British Journal of Haematology|February 19, 2002
Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patientsKarin Karlsson, Mats Strömberg, Jan Liliemark, et al.Leukemia & Lymphoma|October 3, 2012
Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesisFie Juhl Vojdeman, Jesper Jurlander, Mars van't Veer, et al.Pageof 12